FERROUS CITRATE FE 59 Drug Patent Profile
✉ Email this page to a colleague
When do Ferrous Citrate Fe 59 patents expire, and when can generic versions of Ferrous Citrate Fe 59 launch?
Ferrous Citrate Fe 59 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in FERROUS CITRATE FE 59 is ferrous citrate, fe-59. There are thirteen drug master file entries for this compound. Additional details are available on the ferrous citrate, fe-59 profile page.
Summary for FERROUS CITRATE FE 59
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 3 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FERROUS CITRATE FE 59 at DailyMed |
Recent Clinical Trials for FERROUS CITRATE FE 59
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Neopharma Japan Co., Ltd. | Phase 2 |
Parexel | Phase 2 |
University of Alabama at Birmingham | N/A |
US Patents and Regulatory Information for FERROUS CITRATE FE 59
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt | FERROUS CITRATE FE 59 | ferrous citrate, fe-59 | INJECTABLE;INJECTION | 016729-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |